Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in unresectable or borderline resectable pancreatic adenocarcinoma
| Autor: | C. Fugazza, Gianpaolo Balzano, M. Chiaravalli, Claudio Doglioni, Stefano Crippa, A. Costantino, G. Pepe, Paolo Giorgio Arcidiacono, D. Ceraulo, Roberto Nicoletti, Luca Gianni, Massimo Falconi, Paolo Passoni, Chiara Pircher, Silvia Zanon, Michele Reni |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
Cisplatin medicine.medical_specialty business.industry Hematology medicine.disease Gemcitabine Capecitabine 03 medical and health sciences Regimen 0302 clinical medicine Borderline resectable 030220 oncology & carcinogenesis Internal medicine Medicine Adenocarcinoma 030211 gastroenterology & hepatology business medicine.drug Nab-paclitaxel |
| Zdroj: | Annals of Oncology. 27:vi230 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdw371.73 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|